David Watson, Director of Pricing and Reimbursement at the ABPI, comments on the Department of Health's new consultation on the statutory scheme.
David said: "The Department of Health has today announced a new consultation on the statutory scheme.
"This scheme applies to companies selling branded medicines, who have chosen not to join the PPRS. The Department is consulting on a number of options, including its preferred option of moving to a completely different approach whereby companies would make percentage payments on sales rather than price cuts.
"We are concerned that this consultation sends out further negative signals globally about the UK's willingness to pay for new and innovative medicines for patients.
"Moreover, given that the last consultation on this scheme took place less than one year ago, we are concerned that further changes to the scheme may create uncertainty in the UK pharmaceutical market.
"We will of course be making a full response."
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com